1,193
Views
41
CrossRef citations to date
0
Altmetric
Drug Profile

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine

, , , , , , , , , , , & show all
Pages 461-477 | Received 28 Dec 2017, Accepted 30 May 2018, Published online: 22 Jun 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (9)

Ray Borrow, Federico Martinón-Torres, Véronique Abitbol, Anar Andani, Scott Preiss, Alessandro Muzzi, Laura Serino & Woo-Yun Sohn. (2023) Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness. Expert Review of Vaccines 22:1, pages 738-748.
Read now
Juan Xu, Yuquan Chen, Mengmeng Yue, Jianxing Yu, Fuyi Han, Li Xu & Zhujun Shao. (2022) Prevalence of Neisseria meningitidis serogroups in invasive meningococcal disease in China, 2010 - 2020: a systematic review and meta-analysis. Human Vaccines & Immunotherapeutics 18:5.
Read now
Jamie Findlow, Ray Borrow, David S. Stephens, Paul Liberator, Annaliesa S. Anderson, Paul Balmer & Luis Jodar. (2022) Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage. Expert Review of Vaccines 21:6, pages 753-769.
Read now
Yinghua Xu, Yanan Li, Shanshan Wang, Maoguang Li, Miao Xu & Qiang Ye. (2021) Meningococcal vaccines in China. Human Vaccines & Immunotherapeutics 17:7, pages 2197-2204.
Read now
Marco Aurelio P. Safadi, Federico Martinón-Torres, Lidia Serra, Cynthia Burman & Jessica Presa. (2021) Translating meningococcal serogroup B vaccines for healthcare professionals. Expert Review of Vaccines 20:4, pages 401-414.
Read now
Irene Rivero-Calle, Jose Gómez-Rial, Louis Bont, Bradford D. Gessner, Melvin Kohn, Ron Dagan, Daniel C. Payne, Laia Bruni, Andrew J. Pollard, Adolfo García-Sastre, Denise L. Faustman, Albert Osterhaus, Robb Butler, Francisco Giménez Sánchez, Francisco Álvarez, Myrsini Kaforou, Xabier Bello & Federico Martinón-Torres. (2021) TIPICO X: report of the 10th interactive infectious disease workshop on infectious diseases and vaccines. Human Vaccines & Immunotherapeutics 17:3, pages 759-772.
Read now
Angee McDaniel, Amanda Dempsey & Amit Srivastava. (2019) A physician’s guide to the 2-dose schedule of MenB-FHbp vaccine. Human Vaccines & Immunotherapeutics 15:11, pages 2729-2737.
Read now
Jamie Findlow, Charles Nuttens & Paula Kriz. (2019) Introduction of a second MenB vaccine into Europe – needs and opportunities for public health. Expert Review of Vaccines 18:3, pages 225-239.
Read now

Articles from other publishers (32)

James Peterson, Daniel Drazan, Hanna Czajka, Jason Maguire, Jean-Louis Pregaldien, IIkka Seppa, Roger Maansson, Robert O'Neill, Paul Balmer, Luis Jodar, Kathrin U Jansen, Annaliesa S Anderson, John L Perez & Johannes Beeslaar. (2023) Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial. The Lancet Infectious Diseases 23:12, pages 1370-1382.
Crossref
George Kassianos, Osamah Barasheed, Victoria Abbing-Karahagopian, Mansour Khalaf, Serdar Ozturk, Angelika Banzhoff & Selim Badur. (2023) Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review. Infectious Diseases and Therapy 12:9, pages 2193-2219.
Crossref
Bing Cai, Paula Peyrani, Johannes Beeslaar, Cindy Burman & Paul Balmer. (2023) Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp. Vaccine 41:17, pages 2729-2733.
Crossref
Alessandro Muzzi, Margherita Bodini, Nadav Topaz, Vega Masignani, Kumaran Vadivelu, Henju Marjuki, Xin Wang, Laura Serino & Duccio Medini. (2022) Genetic Features of a Representative Panel of 110 Meningococcal B Isolates to Assess the Efficacy of Meningococcal B Vaccines. mSphere 7:5.
Crossref
Selim Badur, Mansour Khalaf, Serdar Öztürk, Rajaa Al-Raddadi, Ashraf Amir, Fayssal Farahat & Atef Shibl. (2022) Meningococcal Disease and Immunization Activities in Hajj and Umrah Pilgrimage: a review. Infectious Diseases and Therapy 11:4, pages 1343-1369.
Crossref
Giorgia Sulis, Miranda Horn, Ray Borrow & Nicole E. Basta. (2022) A comparison of national vaccination policies to prevent serogroup B meningococcal disease. Vaccine 40:26, pages 3647-3654.
Crossref
Gary S. Marshall, Jaime Fergie, Jessica Presa & Paula Peyrani. (2022) Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review. Infectious Diseases and Therapy 11:3, pages 937-951.
Crossref
Jay Lucidarme, Xilian Bai, Aiswarya Lekshmi, Stephen A. Clark, Laura Willerton, Sonia Ribeiro, Helen Campbell, Laura Serino, Rosita De Paola, Ann Holland, Jennifer Louth, Mary E. Ramsay, Shamez N. Ladhani & Ray Borrow. (2022) Invasive serogroup B meningococci in England following three years of 4CMenB vaccination – First real-world data. Journal of Infection 84:2, pages 136-144.
Crossref
Yi Mo, Wenjian Fang, Hong Li, Junji Chen, Xiaohua Hu, Bin Wang, Zhengli Feng, Honghua Shi, Ying He, Dong Huang, Zhaojun Mo, Qiang Ye & Lin Du. (2021) Safety and Immunogenicity of a Shigella Bivalent Conjugate Vaccine (ZF0901) in 3-Month- to 5-Year-Old Children in China. Vaccines 10:1, pages 33.
Crossref
Selim Badur, Mona A. Al Dabbagh, Atef M. Shibl, Fayssal M. Farahat, Serdar Öztürk, Debasish Saha & Mansour Khalaf. (2021) The Epidemiology of Invasive Meningococcal Disease in the Kingdom of Saudi Arabia: A Narrative Review with Updated Analysis. Infectious Diseases and Therapy 10:4, pages 2035-2049.
Crossref
Elissa G. Currie & Scott D. Gray-Owen. (2021) Exploring the Ability of Meningococcal Vaccines to Elicit Mucosal Immunity: Insights from Humans and Mice. Pathogens 10:7, pages 906.
Crossref
Lars Østergaard, Timo Vesikari, Shelly D. Senders, Carl-Erik Flodmark, Pavel Kosina, Han-Qing Jiang, Jason D. Maguire, Judith Absalon, Kathrin U. Jansen, Shannon L. Harris, Roger Maansson, Paul Balmer, Johannes Beeslaar & John L. Perez. (2021) Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months. Vaccine 39:32, pages 4545-4554.
Crossref
Alessia Biolchi, Sara Tomei, Brunella Brunelli, Maria Giuliani, Stefania Bambini, Ray Borrow, Heike Claus, Maria Cecilia O. Gorla, Eva Hong, Ana Paula S. Lemos, Jay Lucidarme, Muhamed-Kheir Taha, Ulrich Vogel, Sonia Budroni, Marzia M. Giuliani, Rino Rappuoli, Philip Boucher & Mariagrazia Pizza. (2020) 4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents. Infectious Diseases and Therapy 10:1, pages 307-316.
Crossref
Ray Borrow, Muhamed-Kheir Taha, Marzia Monica Giuliani, Mariagrazia Pizza, Angelika Banzhoff & Rafik Bekkat-Berkani. (2020) Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence. Journal of Infection 81:6, pages 862-872.
Crossref
Yih-Ling Tzeng, Serena Giuntini, Zachary Berman, Soma Sannigrahi, Dan M. Granoff & David S. Stephens. (2020) Neisseria meningitidis Urethritis Outbreak Isolates Express a Novel Factor H Binding Protein Variant That Is a Potential Target of Group B-Directed Meningococcal (MenB) Vaccines. Infection and Immunity 88:12.
Crossref
Jamie Findlow, Christopher D. Bayliss, Peter T. Beernink, Ray Borrow, Paul Liberator & Paul Balmer. (2020) Broad vaccine protection against Neisseria meningitidis using factor H binding protein. Vaccine 38:49, pages 7716-7727.
Crossref
Stephen A. Clark & Ray Borrow. (2020) Herd Protection against Meningococcal Disease through Vaccination. Microorganisms 8:11, pages 1675.
Crossref
Mariagrazia Pizza, Rafik Bekkat-Berkani & Rino Rappuoli. (2020) Vaccines against Meningococcal Diseases. Microorganisms 8:10, pages 1521.
Crossref
Sydel R. Parikh, Helen Campbell, Julie A. Bettinger, Lee H. Harrison, Helen S Marshall, Federico Martinon-Torres, Marco Aurelio Safadi, Zhujun Shao, Bingqing Zhu, Anne von Gottberg, Ray Borrow, Mary E Ramsay & Shamez N Ladhani. (2020) The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. Journal of Infection 81:4, pages 483-498.
Crossref
Johannes Beeslaar, Paula Peyrani, Judith Absalon, Jason Maguire, Joseph Eiden, Paul Balmer, Roger Maansson & John L. Perez. (2020) Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data. Infectious Diseases and Therapy 9:3, pages 625-639.
Crossref
Shahan Syed, Larisa Viazmina, Riccardo Mager, Seppo Meri & Karita Haapasalo. (2020) Streptococci and the complement system: interplay during infection, inflammation and autoimmunity. FEBS Letters 594:16, pages 2570-2585.
Crossref
Silvia Principato, Mariagrazia Pizza & Rino Rappuoli. (2020) Meningococcal factor H binding protein as immune evasion factor and vaccine antigen. FEBS Letters 594:16, pages 2657-2669.
Crossref
Arno Thibau, Alexander A. Dichter, Diana J. Vaca, Dirk Linke, Adrian Goldman & Volkhard A. J. Kempf. (2019) Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets. Medical Microbiology and Immunology 209:3, pages 243-263.
Crossref
Dominique A. Caugant & Ola B. Brynildsrud. (2019) Neisseria meningitidis: using genomics to understand diversity, evolution and pathogenesis. Nature Reviews Microbiology 18:2, pages 84-96.
Crossref
J. Weigl. (2019) Aufsuchendes Impfen durch das GesundheitsamtField vaccination by the local health department. Prävention und Gesundheitsförderung 15:1, pages 80-87.
Crossref
Mark R Alderson, F Marc LaForce, Ajoke Sobanjo-ter Meulen, Angela Hwang, Marie-Pierre Preziosi & Keith P Klugman. (2019) Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines. The Journal of Infectious Diseases 220:Supplement_4, pages S274-S278.
Crossref
Alastair McAlpine & Manish Sadarangani. (2019) Meningitis vaccines in children. Current Opinion in Infectious Diseases 32:5, pages 510-516.
Crossref
David Ermert, Sanjay Ram & Maisem Laabei. (2019) The hijackers guide to escaping complement: Lessons learned from pathogens. Molecular Immunology 114, pages 49-61.
Crossref
Techawiwattanaboon, Barnier-Quer, Palaga, Jacquet, Collin, Sangjun, Komanee, Piboonpocanun & Patarakul. (2019) Reduced Renal Colonization and Enhanced Protection by Leptospiral Factor H Binding Proteins as a Multisubunit Vaccine Against Leptospirosis in Hamsters. Vaccines 7:3, pages 95.
Crossref
Philip S. Watson, Patricia L. Novy & Leonard R. Friedland. (2019) Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease. International Journal of Infectious Diseases 85, pages 22-27.
Crossref
Stephen A. Clark, Jay Lucidarme, Georgina Angel, Aiswarya Lekshmi, Begonia Morales-Aza, Laura Willerton, Helen Campbell, Steve J. Gray, Shamez N. Ladhani, Mike Wade, Mary Ramsay, Julie Yates, Adam Finn & Ray Borrow. (2019) Outbreak strain characterisation and pharyngeal carriage detection following a protracted group B meningococcal outbreak in adolescents in South-West England. Scientific Reports 9:1.
Crossref
Michael P. Veve & Vasilios Athans. 2019. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions 351 372 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.